SGRY

Surgery Partners, Inc.

47
Fundamentals51/ 100
Valuation50/ 100
Upside potential59/ 100
Risk potential32/ 100

SGRY lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover, though they disagree widely on how much.

SGRY Fundamentals

MetricStatus
Stable
Stable
Stable
Weak

SGRY's revenue, profitability and cash flow are currently stable, but its balance sheet is weak.

SGRY PE Valuation

SGRY has no meaningful PE right now: it lost money over the past year.

SGRY Forward outlook

MetricOutlook
--
Growth
Decline
Strongly weakening
Limited
Low

Analysts expect SGRY's earnings to grow, but its revenue and profitability to decline. However, they disagree widely on these estimates.

SGRY Risk to reward

ScenarioChangePrice
Upside+47%$39.14
Downside-32%$18.00

Calculated from the latest close: $26.58 on Nov 12.

SGRY's one-year upside scenario is somewhat larger than its downside: +47% against −32%.

SGRY Earnings Per Share

Q4 2023: $-0.09Q1 2024: $0.01Q2 2024: $-0.26Q3 2024: $-0.47Q4 2024: $-1.33Q1 2025: $-1.53Q2 2025: $-1.43Q3 2025: $-1.36Q4 2025: $-0.61Q1 2026: $-0.59Q2 2026: $-0.69Q3 2026: $-0.67Forward: $0.41
Q4 2023: $-0.09Q1 2024: $0.01Q2 2024: $-0.26Q3 2024: $-0.47Q4 2024: $-1.33Q1 2025: $-1.53Q2 2025: $-1.43Q3 2025: $-1.36Q4 2025: $-0.61Q1 2026: $-0.59Q2 2026: $-0.69Q3 2026: $-0.67Forward: $0.41
QuarterTTM EPSYoY
Forward$0.41—
Q3 2026-$0.67+$0.69
Q2 2026-$0.69+$0.74
Q1 2026-$0.59+$0.94
Q4 2025-$0.61+$0.72
Q3 2025-$1.36-$0.89
Q2 2025-$1.43-$1.17
Q1 2025-$1.53-15400%
Q4 2024-$1.33-$1.24

SGRY is still losing money, but far less than before: $0.67 per share over the past year, against $3.67 at its worst in late 2020.

SGRY Quarterly Revenue

Q4 2023: $735MQ1 2024: $717MQ2 2024: $762MQ3 2024: $770MQ4 2024: $864MQ1 2025: $776MQ2 2025: $826MQ3 2025: $822MQ4 2025: $885MQ1 2026: $811MQ2 2026: $849MQ3 2026: $815M
Q4 2023: $735MQ1 2024: $717MQ2 2024: $762MQ3 2024: $770MQ4 2024: $864MQ1 2025: $776MQ2 2025: $826MQ3 2025: $822MQ4 2025: $885MQ1 2026: $811MQ2 2026: $849MQ3 2026: $815M
QuarterRevenueYoY
Q3 2026$815.3M-0.8%
Q2 2026$848.9M+2.7%
Q1 2026$810.9M+4.5%
Q4 2025$885M+2.4%
Q3 2025$821.5M+6.6%
Q2 2025$826.2M+8.4%
Q1 2025$776M+8.2%
Q4 2024$864.4M+18%

SGRY's revenue grew through 2024 and has held roughly level since: $815M last quarter, about level with the same quarter a year ago.

SGRY Free Cash Flow

Q4 2023: $43MQ1 2024: $20MQ2 2024: $56MQ3 2024: $45MQ4 2024: $89MQ1 2025: −$17MQ2 2025: $58MQ3 2025: $64MQ4 2025: $91MQ1 2026: −$4MQ2 2026: $38MQ3 2026: $79M
Q4 2023: $43MQ1 2024: $20MQ2 2024: $56MQ3 2024: $45MQ4 2024: $89MQ1 2025: −$17MQ2 2025: $58MQ3 2025: $64MQ4 2025: $91MQ1 2026: −$4MQ2 2026: $38MQ3 2026: $79M
QuarterFree cash flowYoY
Q3 2026$79M+24%
Q2 2026$37.5M-35%
Q1 2026-$4.3M+$12.4M
Q4 2025$90.6M+1.7%
Q3 2025$63.8M+42%
Q2 2025$57.9M+3.6%
Q1 2025-$16.7M-185%
Q4 2024$89.1M+108%

SGRY generated $203M in free cash flow over the past year, up 4.5% from the year before.

SGRY Total Shares

Q4 2023: 126MQ1 2024: 126MQ2 2024: 126MQ3 2024: 126MQ4 2024: 126MQ1 2025: 127MQ2 2025: 127MQ3 2025: 127MQ4 2025: 127MQ1 2026: 128MQ2 2026: 129MQ3 2026: 129M
Q4 2023: 126MQ1 2024: 126MQ2 2024: 126MQ3 2024: 126MQ4 2024: 126MQ1 2025: 127MQ2 2025: 127MQ3 2025: 127MQ4 2025: 127MQ1 2026: 128MQ2 2026: 129MQ3 2026: 129M
PeriodChange %Net change
Quarterly0%+40K shares
1 year+1.3%+1.7M shares
3 years+2.5%+3.1M shares
5 years+86%+59.6M shares
Available history+167%+80.6M shares

SGRY has 129M diluted shares, up 1.3% from a year ago.

SGRY Net Leverage

Q4 2023: 5.8xQ1 2024: 5.7xQ2 2024: 6.2xQ3 2024: 6.3xQ4 2024: 6.2xQ1 2025: 6.8xQ2 2025: 6.4xQ3 2025: 6.0xQ4 2025: 6.1xQ1 2026: 6.2xQ2 2026: 6.3xQ3 2026: 5.0x
Q4 2023: 5.8xQ1 2024: 5.7xQ2 2024: 6.2xQ3 2024: 6.3xQ4 2024: 6.2xQ1 2025: 6.8xQ2 2025: 6.4xQ3 2025: 6.0xQ4 2025: 6.1xQ1 2026: 6.2xQ2 2026: 6.3xQ3 2026: 5.0x
QuarterNet LeverageStatus
Q3 20265.0xHigh
Q2 20266.3xHigh
Q1 20266.2xHigh
Q4 20256.1xHigh
Q3 20256.0xHigh
Q2 20256.4xHigh
Q1 20256.8xHigh
Q4 20246.2xHigh

SGRY's net debt is about 5.0 years of its operating earnings (EBITDA), down from 6.0 years a year ago.

SGRY Weekly Momentum

MetricValueStatus
RSI79.5Overbought
Stochastic97.4Overbought

SGRY's weekly RSI is 79 (overbought) and its Stochastic is 97 (overbought).

SGRY PE vs Healthcare Sector

MetricSGRYSector medianRelative
PEN/A26x—

SGRY has no meaningful PE right now: it lost money over the past year.

SGRY Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$18.147% above
20 week MA$16.363% above
50 week MA$15.275% above
100 week MA$18.643% above
200 week MA$25.06.5% above

SGRY has climbed back above all five of its weekly moving averages, and it's now 6.5% above its 200-week average.

SGRY Yearly ROI

YearStart priceEnd priceROI
2020$15.5$27.8+79%
2021$27.8$53.5+92%
2022$53.5$26.7-50%
2023$26.7$32.0+20%
2024$32.0$20.9-35%
2025$20.9$15.9-24%
2026 YTD$15.9$26.6+67%

SGRY is up 67% so far in 2026, after finishing lower in three of the previous six years.

Give your agent the market.

Get API key